Please login to the form below

Not currently logged in
Email:
Password:

Novartis set to cut UK workforce

Novartis is consulting with staff at its Horsham plant on proposals to reduce the workforce by 550

Novartis is set to cut around 550 jobs as it restructures operations at its Horsham, UK, facility.

There are currently about 950 staff working at the site, with the number set to be reduced to around 400 over the next two years.

The company said the proposals are subject to an employee consultation and final board approval.

Sue Webb, general manager, UK & Ireland and country president, said: "Novartis is continuously evaluating its resource allocation to ensure that the organisation is highly flexible and able to proactively adapt to external challenges which best meet the needs of its customers.

"With significant changes in healthcare systems aimed to contain or cut cost, this critical assessment and the subsequent potential changes to the Novartis UK organisation are key to maintain significant investment in innovative drugs and our research efforts in the UK."

The site is shared by: Novartis Pharmaceuticals, Novartis Institutes for BioMedical Research (NIBR), and Novartis Consumer Health.

The news follows Pfizer's decision to close its facility in Kent, with the loss of 2,400 jobs.

17th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics